One sure hopes that for Ocata and for the hopes of all those afflicted, Ocata is able to finalize a non dilution solution to continue Dr. Lanza's work in Phase 11. This will provide a much needed fundamental and psychological boost to the stock, as well as firm up Ocata as an investment, albeit share price-wise probably short-lived.
A dilutive solution, still helps the company to continue clinicals, but continues undermining the value of one's investment.
For those afflicted and for Dr. Lanza, here's hoping for something good.
News 
Market Data 
Discover 
AI
